Patents Assigned to Noxxon Pharma AG
  • C5a binding nucleic acids
    Patent number: 9518265
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3? [SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: December 13, 2016
    Assignee: NOXXON Pharma AG
    Inventors: Kai Hohlig, Axel Vater, Klaus Buchner, Christian Maasch, Sven Klussmann
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Publication number: 20160355821
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Application
    Filed: July 3, 2016
    Publication date: December 8, 2016
    Applicant: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • SDF-1 Binding Nucleic Acids and the Use Thereof
    Publication number: 20160326531
    Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 10, 2016
    Applicant: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • Synthesis of L-Nucleic Acids by Means of an Enzyme
    Publication number: 20160304926
    Abstract: The present invention is related to a method for adding one or more L-nucleotides to the 3?end of a first L-nucleic acid, wherein the method comprises the step of reacting the one or more L-nucleotides with the first L-nucleic acid in the presence of a protein comprising a mutant enzymatic activity exhibiting moiety, wherein the enzymatic activity is capable of adding one or more L-nucleotides to the 3? end of the first L-nucleic acid, wherein the mutant enzymatic activity exhibiting moiety comprises an amino acid sequence, wherein the amino acids of the amino acid sequence are D-amino acids, wherein the mutant enzymatic activity exhibiting moiety is a variant of an enzymatic activity exhibiting moiety, wherein the enzymatic activity exhibiting moiety consists of an amino acid sequence according to SEQ ID NO: 15 and wherein the amino acids of the amino acid sequence according to SEQ ID NO: 15 are D-amino acids, wherein the amino acid sequence of the mutant enzymatic activity exhibiting moiety differs from the
    Type: Application
    Filed: November 20, 2014
    Publication date: October 20, 2016
    Applicant: NOXXON Pharma AG
    Inventors: Andreas Pech, Florian Jarosch, Michael Jahnz, Sven Klussmann, Ralf David
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Patent number: 9387221
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: July 12, 2016
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • Enzymatic Synthesis of L-Nucleic Acids
    Publication number: 20150337348
    Abstract: The present invention is related to a method for adding one or more L-nucleotides to the 3? end of a first L-nucleic acid, wherein the method comprises the step of reacting the one or more L-nucleotides with the first L-nucleic acid in the presence of a protein comprising an enzymatic activity exhibiting moiety, wherein the enzymatic activity is capable of adding one or more L-nucleotides to the 3? end of the first L-nucleic acid.
    Type: Application
    Filed: May 16, 2013
    Publication date: November 26, 2015
    Applicant: NOXXON Pharma AG
    Inventors: Andreas Pech, Ralf David, Florian Jarosch, Michael Jahnz, Sven Klussmann
  • Nucleic acids specifically binding CGRP
    Patent number: 9163243
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to CGRP, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? HWn1n2YGGAn3An4UMn5n6Yn7n8n9n10n11Kn12Rn13ADn14n15 ARn16Un17Cn18n19Un20n21 3? [SEQ ID NO: 99], wherein H, W, Y, G, A, U, M, B, K, R, D, C are ribonucleotides, and n1 is R or dG, n2 is U or dT, n3 is K or dG, n4 is C or dC, n5 is M or dC, n6 is B or dU, n7 is N or dG, n8 is Y or dT, n9 is N or dC, n10 is R or dG, n11 is V or dA, n12 is K or dT or dU, n13 is G or dG, n14 is A or dA, n15 is U or dT, n16 is R or dG, n17 is Y or dC, n18 is C or dC, n19 is B or dC, n20 is C or dC, n21 is C or dC, and dG, dT, dC, dA and dU are 2?-deoxyribonucleotides.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: October 20, 2015
    Assignee: NOXXON Pharma AG
    Inventors: Simone Schulzchen, Werner Purschke, Florian Jarosch, Kai Hohlig, Christian Maasch, Sven Klussmann
  • Use of spiegelmers
    Patent number: 9074214
    Abstract: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: July 7, 2015
    Assignee: NOXXON Pharma AG
    Inventors: Axel Vater, Christian Maasch, Sven Klussmann, Werner Purschke, Dirk Eulberg, Florian Jarosch, Klaus Buchner
  • MCP-1 Binding Nucleic Acids and Use Thereof
    Publication number: 20150141496
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to MCP-I, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney disease and systemic lupus erythematosus.
    Type: Application
    Filed: May 15, 2014
    Publication date: May 21, 2015
    Applicant: NOXXON PHARMA AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
  • SDF-1 binding nucleic acids
    Patent number: 9035038
    Abstract: The present invention is related to an L nucleic acid that binds to an SDF-1.
    Type: Grant
    Filed: October 13, 2012
    Date of Patent: May 19, 2015
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • Lipid binding nucleic acids
    Patent number: 8871920
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to a lipid.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: October 28, 2014
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Sven Klussmann, Klaus Buchner, Frank Schwobel, Kai Hoehlig
  • Hepcidin binding nucleic acids
    Patent number: 8841431
    Abstract: The present invention is related to a nucleic acid capable of binding to hepcidin.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: September 23, 2014
    Assignee: NOXXON Pharma AG
    Inventors: Simone Sell, Frank Morich, Christian Maasch, Sven Klussmann, Nicole Dinse, Klaus Buchner, Frank Schwobel
  • SDF-1 binding nucleic acids and the use thereof
    Patent number: 8772257
    Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 8, 2014
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • MCP-1 binding nucleic acids
    Patent number: 8691784
    Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: April 8, 2014
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
  • Novel Use of Spiegelmers
    Publication number: 20130337049
    Abstract: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.
    Type: Application
    Filed: July 30, 2013
    Publication date: December 19, 2013
    Applicant: NOXXON Pharma AG
    Inventors: Axel Vater, Christian Maasch, Sven Klussmann, Werner Purschke, Dirk Eulberg, Florian Jarosch, Klaus Buchner
  • SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment
    Publication number: 20130310442
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Application
    Filed: September 9, 2011
    Publication date: November 21, 2013
    Applicant: NOXXON PHARMA AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • C5a binding nucleic acids
    Patent number: 8507456
    Abstract: The present invention is related to a nucleic acid, preferably binding to C5a, selected from the group comprising type A nucleic acids, type B nucleic acids, type C nucleic acids, type D nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 73 to 79.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: August 13, 2013
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
  • Use of spiegelmers to inhibit an intracellular target molecule
    Patent number: 8497250
    Abstract: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: July 30, 2013
    Assignee: NOXXON Pharma AG
    Inventors: Axel Vater, Christian Maasch, Sven Klussmann, Werner Purschke, Dirk Eulberg, Florian Jarosch, Klaus Buchner
  • Lipid Binding Nucleic Acids
    Publication number: 20130165501
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to a lipid.
    Type: Application
    Filed: April 21, 2011
    Publication date: June 27, 2013
    Applicant: NOXXON PHARMA AG
    Inventors: Werner Purschke, Sven Klussmann, Klaus Buchner, Frank Schwoebel, Kai Hoehlig
  • Vasopressin-binding L-nucleic acid
    Patent number: 8383789
    Abstract: The present invention relates to a vasopressin-binding nucleic acid, characterized in that the nucleic acid contains a stretch Box1 and a stretch Box2, in which Box1 comprises the sequence GUGGW and W=A or U, preferably W=U, and in which Box2 comprises a sequence of about 18 to 24 nucleotides, preferably 21 nucleotides, and a group (G)n is contained four times in the sequence, in which n=2, 3 or 4.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: February 26, 2013
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Dirk Eulberg, Sven Klussmann, Ingo Rohl, Axel Vater